Citation Impact
Citing Papers
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
2017
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Breast cancer
2019 Standout
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8+ effector T cell responses
2016
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Breast cancer
2016 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
2014
Pyroptosis: mechanisms and diseases
2021 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
2017
Informative censoring — a neglected cause of bias in oncology trials
2020
Management of glioblastoma: State of the art and future directions
2020 Standout
A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma
2015
Breast Cancer Treatment
2019 Standout
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
2014
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
2016
Works of T Taran being referenced
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014